Best GLP-1 Providers for Medicare Patients Starting July 2026
Updated June 2026 · Medicare GLP-1 Bridge launches July 1, 2026
⚡ TL;DR — What Medicare Patients Need to Know
Starting July 1, 2026: Medicare's GLP-1 Bridge program covers brand-name Wegovy, Zepbound, and Foundayo at $50/month for eligible beneficiaries. Right now (June 2026): Medicare doesn't cover GLP-1 for weight loss. Cash-pay options through providers like YourEra Health ($99/mo) and GobyMeds ($99/mo) offer the most affordable bridge to July 1.
📅 Key Date: July 1, 2026
The Medicare GLP-1 Bridge program launches July 1, 2026, making brand-name GLP-1 medications available to eligible Medicare beneficiaries at $50 per month. This guide covers both your options right now and what to expect when coverage begins.
What the Medicare GLP-1 Bridge program covers
The Medicare GLP-1 Bridge, authorized as part of the broader Medicare drug pricing reforms, allows Medicare Part D beneficiaries to access FDA-approved GLP-1 medications for weight loss at a fixed $50 monthly copay. The covered medications include Wegovy (injectable semaglutide), Zepbound (injectable tirzepatide), and Foundayo (oral orforglipron).
This is a significant policy shift. Previously, Medicare explicitly excluded coverage of weight-loss medications under Part D. The Bridge program creates a new carve-out that recognizes the cardiovascular, metabolic, and cost-reduction benefits of GLP-1 treatment for Medicare-eligible patients.
Who qualifies
Eligibility for the Medicare GLP-1 Bridge requires meeting all of the following criteria. You must be enrolled in a Medicare Part D prescription drug plan. Your BMI must be 30 or higher (obese), or 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, cardiovascular disease, hypertension, dyslipidemia, or obstructive sleep apnea. A licensed prescriber must determine that GLP-1 medication is medically appropriate for you.
Notably, the Bridge program covers brand-name FDA-approved medications only — not compounded GLP-1 alternatives. This is an important distinction for patients currently using compounded semaglutide or tirzepatide from telehealth providers.
Your options right now (June 2026)
If you're a Medicare patient interested in GLP-1 medication and don't want to wait until July 1, here are your current options.
Cash-Pay Compounded Providers
Since Medicare doesn't currently cover GLP-1 for weight loss, Medicare patients have been using cash-pay compounded options just like uninsured patients. The most affordable options right now are:
YourEra Health
$99/mo any dose · LegitScript certified · FSA/HSA accepted
For Medicare patients bridging the gap to July 1 coverage, YourEra's $99 flat-rate pricing minimizes out-of-pocket costs during the waiting period. The flat-rate model means your cost stays at $99 even as your dose increases — important for patients who want to start treatment now and transition to Medicare coverage when it launches. If you use an HSA from a previous employer, the cost becomes pre-tax.
See Plans → Paid linkGobyMeds
From $99/mo · LegitScript certified · Code x7X72r saves $25
GobyMeds matches the $99 monthly price with an additional $25-off code for first-month savings. LegitScript certification provides the quality assurance that matters especially for patients on multiple medications — which most Medicare beneficiaries are.
Get Started → Paid linkBrand-Name Access (Self-Pay)
Sesame Care
From $149/mo · FDA-approved Wegovy, Ozempic, Zepbound
If you prefer to start with brand-name FDA-approved medication now and transition to Medicare coverage in July, Sesame Care provides access to the same medications the Bridge will cover. Starting on brand-name now means no medication switch when Medicare kicks in — just a billing change from self-pay to Medicare Part D.
Get Started → Paid linkHow to prepare for July 1
Your Medicare GLP-1 Timeline
Transitioning from compounded to brand-name
If you're currently taking compounded semaglutide and plan to transition to brand-name Wegovy through Medicare on July 1, your prescriber will need to map your current compounded dose to the equivalent Wegovy dose tier. Compounded semaglutide uses milligram dosing while Wegovy uses pre-filled pen doses, so the transition should be coordinated with your provider to ensure continuity.
For patients currently on compounded tirzepatide, the transition to Zepbound follows a similar process. Your provider will help bridge the dosing to avoid any gap in treatment or the side effects that can come with restarting after a break.
What if you're not eligible?
Patients who don't qualify for the Medicare GLP-1 Bridge — whether due to BMI requirements, Medicare Advantage plan restrictions, or other factors — still have access to the full range of cash-pay options. The most affordable compounded providers at $99 per month (YourEra Health and GobyMeds) remain available regardless of insurance status. The TrumpRx program also offers brand-name medications at $245 per month for self-pay patients who prefer FDA-approved options without the Bridge's eligibility requirements.
The bottom line for Medicare patients
July 1, 2026, changes everything for Medicare patients interested in GLP-1 treatment. Brand-name medication at $50 per month is an extraordinary value — likely the cheapest legitimate GLP-1 pathway available to anyone in the United States. If you're eligible, prepare now so you can start the day coverage begins.
If you can't wait, cash-pay compounded options through YourEra Health (Paid link) or GobyMeds (Paid link) at $99 per month provide an affordable bridge until Medicare coverage launches.